In last trading session, BioAtla Inc (NASDAQ:BCAB) saw 0.49 million shares changing hands with its beta currently measuring 1.08. Company’s recent per share price level of $0.34 trading at $0.02 or 6.05% at ring of the bell on the day assigns it a market valuation of $19.95M. That closing price of BCAB’s stock is at a discount of -1082.35% from its 52-week high price of $4.02 and is indicating a premium of 29.41% from its 52-week low price of $0.24. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.82 million shares which gives us an average trading volume of 1.13 million if we extend that period to 3-months.
For BioAtla Inc (BCAB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.38 in the current quarter.
BioAtla Inc (NASDAQ:BCAB) trade information
Upright in the green during last session for gaining 6.05%, in the last five days BCAB remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $0.34 price level, adding 4.74% to its value on the day. BioAtla Inc’s shares saw a change of -41.85% in year-to-date performance and have moved -0.32% in past 5-day. BioAtla Inc (NASDAQ:BCAB) showed a performance of -18.10% in past 30-days. Number of shares sold short was 3.18 million shares which calculate 3.46 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 93.2% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -1370.59% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1370.59% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -25.30% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 40.93% while estimates for its earnings growth in next 5 years are of 18.02%.
BioAtla Inc (NASDAQ:BCAB)’s Major holders
Insiders are in possession of 8.29% of company’s total shares while institution are holding 46.23 percent of that, with stock having share float percentage of 50.41%. Investors also watch the number of corporate investors in a company very closely, which is 46.23% institutions for BioAtla Inc that are currently holding shares of the company. SOLEUS CAPITAL MANAGEMENT, L.P. is the top institutional holder at BCAB for having 3.9 million shares of worth $5.34 million. And as of 2024-06-30, it was holding 8.0915 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.89 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.9205 of outstanding shares, having a total worth of $2.58 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.22 shares of worth $0.42 million or 2.52% of the total outstanding shares. The later fund manager was in possession of 549.45 shares on Dec 31, 2024 , making its stake of worth around $0.19 million in the company or a holder of 1.14% of company’s stock.
